CSIR Central

Compulsory Licensing of Patented Drugs under National Emergency

IR@NISCAIR: CSIR-NISCAIR, New Delhi - ONLINE PERIODICALS REPOSITORY (NOPR)

View Archive Info
 
 
Field Value
 
Title Compulsory Licensing of Patented Drugs under National Emergency
 
Creator Asok, Aswathy
 
Subject Compulsory license
Patent
National emergency
TRIPS Agreement
Doha Declaration
HIV/AIDS
 
Description 270-275
Patent protection to pharmaceutical products by the TRIPS Agreement had made serious concerns in the developing countries regarding accessibility, availability and affordability of life saving drugs. TRIPS Agreement, at the same provided flexibilities to the member countries to even off the adverse effects of pharmaceutical patent system especially in cases involving public health. National emergency, being such flexibility allows member countries to invoke compulsory license for accessing life-saving drugs in cases of national emergency without any pre-conditions. By the Doha Declaration the freedom is also vested upon the individual countries to define the term ‘national emergency’. This triggers apprehension among the patentees about the abuse of such wide discretion by these countries. But these concerns are found negative by the analysis of case studies of compulsory license issued on national emergency. Countries are very cautious while invoking this provision.
 
Date 2018-01-11T06:10:37Z
2018-01-11T06:10:37Z
2017-09
 
Type Article
 
Identifier 0975-1076 (Online); 0971-7544 (Print)
http://nopr.niscair.res.in/handle/123456789/43406
 
Language en_US
 
Rights <img src='http://nopr.niscair.res.in/image/cc-license-sml.png'> <a href='http://creativecommons.org/licenses/by-nc-nd/2.5/in' target='_blank'>CC Attribution-Noncommercial-No Derivative Works 2.5 India</a>
 
Publisher NISCAIR-CSIR, India
 
Source JIPR Vol.22(5) [September 2017]